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The incidence rate of prostate cancer in the UK has increased over
several decades. It is thought that this was partly due to increased
detection of early stage cancers through use of transurethral
prostatectomy and, in the 1990s, the serum prostate specific
antigen (PSA) test to aid diagnosis, mostly in symptomatic men
(Chamberlain et al, 1997; Oliver et al, 2000). 
The high rate of PSA testing in the USA has been linked to the
very high rise in incidence, a shift towards increasing diagnosis of
early stage cancers, and more recently a decline in age-specific
mortality rates (Collins et al, 2000; Jacobsen et al, 1995), although
other factors could have caused the trends in mortality (Oliver 
et al, 2000). Although the rate of testing is likely to be lower in the
UK, there are no routine data with which to assess the extent of
PSA testing. Data from a large general practice database
(Chamberlain et al, 1997) in the UK, showed that in 1994, 2109
men (1.4%) aged 45 years plus, with no prior history of prostate
cancer, had a PSA test noted on their record. More recent data have
been examined using the same dataset. 
METHODS 
Men aged 45 years plus, with no prior history of prostate cancer or
record of a radical prostatectomy, were identified from the UK
MediPlus® database in 1998 and 1999. The database covered over
150 000 men in this age group registered with around 120 comput-
erized practices. These were a non-random sample of practices
spread throughout the UK selected because of their use of the
System 5 Torex Health GP computer system. A retrospective
analysis was conducted to describe the proportion of males having
a PSA test and the levels of PSA recorded. We studied the annual
rate of PSA testing using the proportion (%) of all men who had a
PSA test within 1 year out of all those in the GP practices. 
RESULTS 
Overall, 3.5% of men aged 45 or older who had no previous record
of prostate cancer (out of a total sample of 160 015) had a PSA test
in a 1-year-period, 1999. The rate increased with age from 1.5% in
men aged 45–54 to 5.2% in men aged 70 or older. There was little
variation between north and south England (Table 1): the rates
overall were 3% and 4%, respectively, although the difference did
seem to be greater in men aged 55 or older than in men aged 45–54
years. The numbers of men tested were too small to conduct a
detailed analysis by age and region. For all ages, the rate of testing
ranged from 0.1% (2 out of 1974) in Oxford to 7.6% (1164 out of
15 417) in Wessex, age standardized to the England and Wales
1997 population aged 45 or older. Among 5626 men who tested
for PSA in 1999, the proportion with levels over 4 ng/ml was
21.3% (Table 2), the proportion increasing with age. There was a
slight increase in the rate of testing from 2.7% in 1998 to 3.5% in
1999. This increase occurred in all age groups. 
DISCUSSION 
The rate of PSA testing in 1999 is more than double the rate
reported for 1994 (3.5% compared with 1.4% [Chamberlain et al,
1997]). Limitations with these data include uncertainly about
completeness related to non-uniform electronic recording, the
possibility that raised PSA results were more likely to be recorded
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Table 1 The proportion of men (%) who had PSA testing over a one year
period, 1999, in men with no prior diagnosis of prostate cancer presented by
age, and north or south England* 
Age (years) 
Area 45–54 55–69 70+ Total 
North % 1.3% 3.5% 4.5% 3.0% 
No. men tested 269 783 750 1802 
Total in practices 20 931 22 678 16 813 60 422 
South % 1.6% 4.7% 5.8% 3.9% 
No. men tested 523 1625 1488 3636 
Total in practices 31 919 34 407 25 728 92 054 
Total % 1.5% 4.2% 5.3% 3.6% 
No. men tested 792 2408 2238 5438 
Total in practices 52 850 57 085 42 541 152 476 
*North: practices in Mersey, North Western, Northern, Trent, West Midlands
and Yorkshire regions; South: practices in East Anglia, North East & West
Thames, Oxford, South East & West Thames, South Western and Wessex
regions; Scotland and Wales were excluded because of small numbers. 
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than low results, the inability to distinguish between asymptomatic
and symptomatic testing, and lack of data on private testing. 
The results highlight the lower rate of PSA testing in the UK
than in the USA, and this may be associated with the lower regis-
tration rate for prostate cancer in the UK. At visits to US primary
care physicians in 1995 and 1996, approximately 7% of men aged
60–79 had a PSA test ordered (Collins et al, 2000). In Minnesota,
6.6% of men aged 50 or more in 1992 received their first PSA test,
and over 40% of men aged 60 or more had had at least one PSA
test in their lifetime (Jacobsen et al, 1995). In the Finnish arm of
the European screening trial (Maattanen et al, 1999), 8.5% of men
aged 55–67 had a PSA level above 4 ng/ml compared with 15.8%
of men aged 55–69 in this survey, suggesting that the latter were
more frequently associated with symptoms that might be either
related to prostate cancer or more commonly to other conditions
such as benign prostatic hypertrophy. 
The quality of data available to study the impact of the PSA test
for both diagnostic purposes and testing in asymptomatic men on
the health service needs to be improved. 
At present the use of the PSA test to aid diagnosis may be
costing the NHS nearly £2 million annually, but it is unclear what
impact this has on the incidence rate and stage of diagnosis. The
Department of Health has recently launched an initiative (the PSA
Informed Choice Project) to meet the needs for information about
the test (http://www.doh.gov.uk/cancer/prostate.htm). It is uncer-
tain what impact this and other initiatives will have on PSA testing
in general practice, but data on the rate of PSA testing would help
to monitor their effects. 
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Table 2 The distribution (%) of men in 1999 with a PSA test according to their level of PSA and age 
Age (years) 
PSA test result (ng/ml) 45–54 % No. 55–69 % No. 70+ % No. All % No.
0–4 95.9% 780 84.2% 2111 66.6% 1534 78.7% 4425 
5–10 2.7% 22 10.9% 274 19.3% 446 13.2% 742 
11–20 0.8% 6 2.8% 71 8.1% 186 4.6% 263 
21+ 0.6% 5 2.1% 52 6.0% 139 3.5% 196 
Total 100 813 100 2508 100 2305 100 5626 
No test recorded 54 597 57 545 42 247 154 389 
Total in practices 55 410 60 053 44 552 160 015 
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